Overview

Calcineurin Free Immunosuppression in Renal Transplant Recipients

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of acute rejection following renal transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Cyclosporine
Cyclosporins
Everolimus
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Sirolimus